U-M Bone Marrow Transplant Program

Bone Marrow Transplantation Program

The Adult Blood and Marrow Transplant (BMT) Program at the University of Michigan is a place where compassionate care, multidisciplinary collaboration and the latest research innovations come together to provide the ideal patient care experience. This is particularly important for patients that require this highly complex and specialized treatment for their condition, including: • leukemia • lymphoma • myelodysplasia • neuroblastoma • bone and soft-tissue sarcomas • brain tumors • other conditions including the failure of a patient’s own bone marrow or certain immunodeficiency disorders More than 200 adult BMT procedures are performed through this program annually, making us one of the largest programs in the Midwest. As one of the largest extracorporeal photopheresis centers in the world, we perform more than 1,000 procedures yearly – primarily for patients with graft–vs.–host disease.

However, it is the people who make up the BMT Program and their unwavering focus on patient-centric care that set us apart. Led by Daniel Couriel, M.D., our dedicated team of transplant specialists, which include nearly 100 physicians, nurses, midlevel practitioners and transplant coordinators, is specially trained in and solely devoted to marrow and hematopoietic stem cell transplantation. We offer this level of care through every aspect of treatment, from the initial patient consult, transplantation, post transplantation care and transition back to everyday life.

Daniel Couriel, M.D. Director, Adult BMT Clinical Program Professor, Hematology and Oncology

Steven Goldstein, M.D. Associate Professor, Hematology and Oncology

John Magenau, M.D. Clinical Assistant Professor, Hematology and Oncology

Brian Parkin, M.D. Assistant Professor, Hematology and Oncology

Attaphol Pawarode, M.D. Clinical Assistant Professor, Hematology and Oncology

Pavin Reddy, M.D., Professor, Hematology and Oncology

Mary Riwes, D.O. Assistant Professor, Hematology and Oncology

Each patient is part of a team consisting of a physician, mid-level provider and nurse, all of whom are transplant subspecialists. The team remains constant throughout the delivery of care, which means that someone who knows the patient is available at any time to provide the ideal patient care experience.

The care team is enhanced by additional specialists who are trained to address the personal and emotional needs of both BMT patients and their caregivers, including psychologists, social workers, nutritionists and many others. This support is fully integrated into the patient’s treatment plan.

Our inpatient and outpatient care are fully integrated in a new state of the art, tertiary care facility with HEPA filtration throughout the entire unit – not just in the rooms. All outpatient care is provided at one location and coordinated to eliminate the need for separate trips to meet with the care team and to receive infusion.

Post-treatment care To reduce readmissions, each patient has a follow-up plan implemented at discharge from the BMT unit, which includes transitioning into the Ambulatory Treatment Center (ATC). This special outpatient clinic, located on the same floor as the inpatient care, allows patients to remain with the same treatment team during the early post-transplant phase until they are ready to transition back to their primary physician. The unit also allows for the possibility of offering outpatient transplants. Without complications, autologous transplant patients can return to their provider in 100 days. Allogeneic transplant patients generally transition back about a year after transplant, provided that they stop taking anti-rejection drugs.

Long-term side effects We have a well-developed long term follow up and survivorship program to deal with long term side effects such as graft–vs.–host. We also have a chronic graft–vs.–host disease clinic which includes physiatry and neuropsychology as well as access to a group of GVHD subspecialists in ophthalmology, gynecology, pulmonology and cardiology.

Research We offer cutting edge research with a broad portfolio to cover many diseases and treatment types. Our clinical research, which is led by Pavan Reddy, M.D., is dedicated largely to finding new and improved strategies to prevent relapse and complications after BMT. In particular, we are focused on reducing the incidence and severity of the common and dangerous complication graft–vs.–host disease. U-M faculty members are recognized nationally and internationally for their expertise in treating acute and chronic GVHD. We are also active in ongoing phase 2 and phase 3 clinical studies in multiple myeloma, acute myelogenous leukemia and lymphoma. These studies are for both our transplant patients as well as those that are non-transplant.

Contact Us Bone Marrow Transplant Clinic C.S. Mott Children’s Hospital 1540 E. Hospital Drive, Floor 7 Ann Arbor, MI 48109

For Referrals: M-LINE 800-962-3555 mcancer.org/bmt

mcancer.org/bmt

University of Michigan Comprehensive Cancer Center Max S. Wicha, M.D., Director; Marcy B. Waldinger, MHSA, Chief Administrative Officer Executive Officers of the University of Michigan Health System

The Regents of the University of Michigan

Michael M.E. Johns, M.D., Interim Executive Vice President for Medical Affairs; James O. Woolliscroft, M.D., Dean, U-M Medical School; T. Anthony Denton, J.D., MHA, Acting Chief Executive Officer, U-M Hospitals and Health Centers; Kathleen Potempa, Ph.D., Dean, School of Nursing.

Mark J. Bernstein, Julia Donovan Darlow, Laurence B. Deitch, Shauna Ryder Diggs, Denise Ilitch, Andrea Fischer Newman, Andrew C. Richner, Katherine E. White, Mark S. Schlissel (ex officio).

The University of Michigan is a non-discriminatory affirmative action employer. Š 2014 The Regents of the University of Michigan 06784 10/2014-.5k/A